Experimental CAR t therapy targets root cause of rare autoimmune disease
NCT ID NCT07573332
First seen May 17, 2026 · Last updated Jun 23, 2026 · Updated 5 times
Summary
This early-stage trial tests whether a new CAR T cell therapy called CC-97540 is safe for people with a rare autoimmune condition called neuromyelitis optica (NMOSD). The study includes 5 adults who are stable on current treatments. The goal is to see if the therapy can remove the harmful antibodies that cause relapses, potentially reducing the need for long-term immune suppression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AQP4+ NMOSD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Southwestern
Dallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CC-97540 (BMS-986353) CAR T cell therapy
What this could lead to
If it works, this could point toward a treatment that removes the harmful antibodies causing NMOSD relapses without lifelong immune suppression.
What could go wrong
This is a very early Phase 1 trial with only 5 participants, so safety and effectiveness are unknown. The therapy involves chemotherapy and carries risks like infections and cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.